RLAY Relay Therapeutics Inc
Company Analysis
Latest News
🔴 Relay Therapeutics is trading 4% down today
Relay Therapeutics is trading 4.03% down now at $18.08, with no clear company-specific catalyst emerging on September 21, 2026. - Recent coverage describes...
🟢 Relay Therapeutics rises 4.1% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
Relay Therapeutics Lands $19 Million Frazier Stake Amid Insider Selling
Frazier Life Sciences Management L.P. acquired 1,015,693 shares of Relay Therapeutics. The new position is valued at approximately $19 million according to a...
Relay Therapeutics Shareholder Sells $116.4 Million Stake After Stock Rally
SVF Pauling (Cayman) Ltd sold 6,000,000 shares of Relay Therapeutics common stock. The transaction occurred on August 25, 2026. The SoftBank Vision Fund...
🔴 Relay Therapeutics falls 4.0% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
Casdin Capital boosts stake in Relay Therapeutics by 11%
Casdin Capital increased its position in clinical-stage biotech firm Relay Therapeutics (RLAY) by 11.21% during the second quarter of 2026, according to a...
🔴 Relay Therapeutics is trading 5% down today; catalyst unconfirmed
Relay Therapeutics is trading 5.15% down now at $19.51, with the catalyst unconfirmed. - No clear company-specific announcement, earnings release, regulatory...
🔴 Relay Therapeutics is trading 4.08% down in pre-market
Relay Therapeutics is trading 4.08% down at $19.73 in pre-market, with the reason for the decline unconfirmed. - It closed at $20.57 on August 25, 2026; no...
🟢 Relay Therapeutics rises 4.1% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🟢 Relay Therapeutics is trading 5% up in after-hours trading after H.C. Wainwright raised target to $29
Relay Therapeutics is trading 5% up at $20.68 in after-hours trading after H.C. Wainwright raised its price target to $29 on August 20, 2026. - After-hours...
🔴 Relay Therapeutics falls 4.0% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Casdin Capital Boosts Stakes in Revolution Medicines & Relay, Trims Genomics Tools
In its second-quarter 13F filing for the period ending June 30, 2026, life-sciences specialist Casdin Capital revealed a portfolio value of $2.0 billion. The...
Alphabet buys $26.4M Relay Therapeutics stake, betting on breast cancer drug
Alphabet Inc. disclosed a new stake in Relay Therapeutics on August 18, 2026. The tech giant purchased 1.41 million shares during the second quarter. This...
🟢 Relay Therapeutics is trading 4.3% up today with no confirmed catalyst
Relay Therapeutics is trading 4.3% up now at $20.72, with the reason for the gain remaining unconfirmed. - Searches found no new company-specific...
Relay Therapeutics Jumps 12% on a Wave of Analyst Upgrades — But Can a Pre-Revenue Biotech Justify a $4 Billion Valuation?
Shares of Relay Therapeutics surged 12.1% to $22.50 on August 13, extending a rally fueled by a cascade of Wall Street upgrades anchored by growing confidence...
🟢 Relay Therapeutics is trading 12% up in pre-market after Citizens raised its price target
Relay Therapeutics is trading 12.11% up now at $22.50 after recent bullish analyst commentary and clinical progress supporting zovegalisib’s development...
🟢 Relay Therapeutics Surges 4.3% Today on Analyst Price Target Hikes Following Strategic Shift Toward Front-Line Breast Cancer
Relay Therapeutics is trading 4.3% up now at $20.62 after several analysts, including Citizens JMP and Goldman Sachs, raised their price targets and reaffirmed...
Relay Therapeutics Inc Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Relay Therapeutics is expected to report a second-quarter loss of $0.41 per share on revenue of $0.96 million, with the stock trading at $18.83 compared to an...
🟢 Relay Therapeutics is trading 4.1% up today amid broader biotech sector strength
Relay Therapeutics is trading 4.1% up at $19.54 today, driven by broader biotech sector strength and a general market rally despite no fresh company-specific...
Relay Therapeutics Insiders Sell Shares, Preceding Critical Zovegalisib Pipeline Update
Three Relay Therapeutics executives sold shares totaling over $82,000 on July 30, 2026. The selling group included the Chief Financial Officer and the...